 |
85 Diseases |  |
38 Trials |
|
38 Trials |  |
1659 News |  |
| «12...234567891011121314 |
- Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial termination: Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=7, Terminated, Sponsor: Joslin Diabetes Center
Recruiting --> Terminated; Treatment differences not detected with 7 point fingerstick monitoring
- Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Enrollment change: Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=7, Terminated, Sponsor: Joslin Diabetes Center
Recruiting --> Terminated; Treatment differences not detected with 7 point fingerstick monitoring N=40 --> 7
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog (clinicaltrials.gov) - Sep 9, 2012
P1, N=43, Completed, Sponsor: Novo Nordisk
- | Apidra (insulin glulisine) / Sanofi
New P4 trial: Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Aug 30, 2012
P4, N=63, Recruiting, Sponsor: Medical University of Warsaw
- Victoza (liraglutide) / Novo Nordisk
New P4 trial: Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics (clinicaltrials.gov) - Jul 29, 2012
P4, N=36, Active, not recruiting, Sponsor: Mountain Diabetes and Endocrine Center
- ||||| NovoLog (insulin aspart) / Novo Nordisk
New P4 trial: Safety and Efficacy of Insulin Aspart in Type 2 Diabetes (clinicaltrials.gov) - Jul 23, 2012
P4, N=123, Completed, Sponsor: Novo Nordisk
- | New P4 trial, Post-transplantation: PTHG: Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia (clinicaltrials.gov) - Jul 22, 2012
P4, N=120, Recruiting, Sponsor: Vancouver General Hospital
- || NovoLog Mix 70/30 (insulin aspart protamine 70%/insulin aspart 30%) / Novo Nordisk, BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk
Trial initiation date: IMPROVE (clinicaltrials.gov) - Jun 14, 2012
P=N/A, N=58223, Completed, Sponsor: Novo Nordisk
N=40 --> 7 Initiation date: Feb 2006 --> Sep 2006
- | NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process in Healthy Japanese (clinicaltrials.gov) - Jun 13, 2012
P1, N=34, Completed, Sponsor: Novo Nordisk
- Enrollment change: Safety and Efficacy Study of NovoRapid (clinicaltrials.gov) - May 23, 2012
P=N/A, N=0, Withdrawn, Sponsor: Novo Nordisk
Initiation date: Feb 2006 --> Sep 2006 N=2500 --> 0
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes (clinicaltrials.gov) - Apr 25, 2012
P4, N=30, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
N=2500 --> 0 Recruiting --> Completed
- | NovoLog (insulin aspart) / Novo Nordisk
New P2 trial, Surgery: Cardiac Surgery Neuroprotection Study in Elders (clinicaltrials.gov) - Mar 21, 2012
P2, N=60, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
- Aspart-PH20 (insulin aspart/rHuPH20) / Halozyme
Enrollment closed: Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM) (clinicaltrials.gov) - Mar 5, 2012
P1, N=36, Active, not recruiting, Sponsor: Halozyme Therapeutics
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Insuman Rapid (recombinant human insulin) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
Enrollment closed: HERMESt: Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study (clinicaltrials.gov) - Mar 1, 2012
P4, N=12, Active, not recruiting, Sponsor: ikfe-CRO GmbH
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- | Aspart-PH20 (insulin aspart/rHuPH20) / Halozyme, Lispro-PH20 (insulin lispro/rHuPH20) / Halozyme
New P4 trial: Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase (clinicaltrials.gov) - Feb 2, 2012
P4, N=25, Active, not recruiting, Sponsor: Halozyme Therapeutics
- NovoLog (insulin aspart) / Novo Nordisk
New P2 trial: Diurnal Variation of Exogenous Peptides (Endogenous Insulin Jurgita II) (clinicaltrials.gov) - Jan 11, 2012
P2, N=10, Completed, Sponsor: Aarhus University Hospital
- | NovoLog Mix 70/30 (insulin aspart protamine 70%/insulin aspart 30%) / Novo Nordisk, BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers (clinicaltrials.gov) - Dec 5, 2011
P1, N=50, Completed, Sponsor: Novo Nordisk
- NovoLog (insulin aspart) / Novo Nordisk
Enrollment open: IINDU: Insulin Infusion Diabetes Ulcer (clinicaltrials.gov) - Dec 5, 2011
P4, N=40, Enrolling by invitation, Sponsor: Karolinska Institutet
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Enrolling by invitation
- | NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process (clinicaltrials.gov) - Dec 4, 2011
P1, N=28, Completed, Sponsor: Novo Nordisk
- ||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical: An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime (clinicaltrials.gov) - Nov 24, 2011
P=N/A, N=2134, Completed, Sponsor: Novo Nordisk
- |||||||||| Humalog pen (insulin lispro) / Eli Lilly
New P3 trial: Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy (clinicaltrials.gov) - Nov 16, 2011
P3, N=120, Completed, Sponsor: Eli Lilly and Company
- | NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: Bioequivalence of Two NovoLog (clinicaltrials.gov) - Oct 30, 2011
P1, N=24, Completed, Sponsor: Novo Nordisk
- NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients (clinicaltrials.gov) - Sep 28, 2011
P4, N=12, Completed, Sponsor: University of Aarhus
Not yet recruiting --> Enrolling by invitation Recruiting --> Completed
- GlucaGen (recombinant glucagon) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone (clinicaltrials.gov) - Sep 22, 2011
P2, N=14, Completed, Sponsor: Legacy Health System
Recruiting --> Completed Active, not recruiting --> Completed
- BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk
Trial completion: HUCKEPACK2: Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids (clinicaltrials.gov) - Sep 21, 2011
P4, N=20, Completed, Sponsor: Medical University of Graz
Active, not recruiting --> Completed Recruiting --> Completed
- | Insuman Rapid (recombinant human insulin) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
New P4 trial: HERMESt: Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study (clinicaltrials.gov) - Aug 14, 2011
P4, N=12, Active, not recruiting, Sponsor: ikfe-CRO GmbH
- Lantus (insulin glargine) / Sanofi, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Enrollment change: ktpump: Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=24, Completed, Sponsor: Arkansas Children's Hospital Research Institute
Recruiting --> Completed N=30 --> 24